News from EAS 2024: Long-term data with lomitapide in HoFH

Long term efficacy and safety data of lomitapide in HoFH

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Causal relationship between elevated Lp(a) levels and CKD risk
Causal relationship between elevated Lp(a) levels and CKD risk
EAS 2024
Causal relationship between elevated Lp(a) levels and CKD risk
- Anne Langsted, MD, PhD
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
EAS 2024
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
- Pasquale Perrone-Filardi, MD, PhD
Encouraging data with APOC3 siRNA in mixed hyperlipidemia
Encouraging data with APOC3 siRNA in mixed hyperlipidemia
EAS 2024
Encouraging data with APOC3 siRNA in mixed hyperlipidemia
- Christie Ballantyne, MD
Rationale for dietary fat recommendations in ASCVD prevention
Rationale for dietary fat recommendations in ASCVD prevention
EAS 2024
Rationale for dietary fat recommendations in ASCVD prevention
- Jacob J. Christensen, PhD